Get to know our clinical trials
Trial of mecbotamab vedotin(BA3011) in monotherapy and in combination with nivolumab in adult patients with metastatic non-small cell lung cancer.
THE OBJECTIVE OF THIS STUDY IS TO DETERMINE THE SAFETY AND EFFICACY OF AN EXPERIMENTAL DRUG CALLED &IQUEST;MECBOTAMAB VEDOTIN (BA3011)&IQUEST; IN DIFFERENT MALIGNANCIES EXPRESSING THE AXL PROTEIN.
- PHASE 2 STUDY TO EVALUATE THE ADMINISTRATION OF MECBOTAMAB VEDOTIN (BA3011) IN MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE HAD DISEASE PROGRESSION DURING TREATMENT WITH A PD-1/L1, EGFR OR ALK INHIBITOR OR INTOLERANCE TO SUCH TREATMENT. IMMUNOTHERAPY
- Code EudraCT: 2022-000135-23
- Protocol number: BA3011-002
- Promoter: BioAtla Inc,
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.